Screen Shot 2016-01-17 at 2.02.09 pm
Saturday, April 25, 2026
29.1
C
Bengaluru
Hot topics
Trump Tariff and the Trade Turbulence – A Salil Kallianpur BlogÂ
Impact of Trump’s 100% tariff on imported patented/innovative drugs...
India’s Medical Devices Market: Strategic Implications and Key Investors
KKR's Investments in India's Medical Devices Market: Strategic Implications...
Indian Pharma November Sales: What Do They Say?
IQVIA's Market Feedback Report (MFR) and PharmaTrac's Acquaint report...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Indian Pharma’s November 2025: How GLP-1s Rewired the Market
Indian pharma wrapped up November 2025 with serious velocity....
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Hot topics
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
Pharma CEO Roundtable – Engaging Doctors – Physical, Digital and Hybrid: Translating Strategy into Action
The MedicinMan 10th Anniversary Special - Pharma CEO Roundtable...
From VUCA to TACO: Thriving in a Chaotic World
From VUCA to TACO: Thriving in a Chaotic World
Leaders...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Newsletter
Get important news delivered directly to your inbox and stay connected!